Join to View Full Profile
2799 W Grand BlvdDetroit, MI 48202
Phone+1 800-653-6568
Fax+1 313-916-3711
Dr. Gadgeel is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1996 - 2000
Wayne State University School of MedicineResidency, Internal Medicine, 1994 - 1996
Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 1993 - 1994
Grant Medical CollegeClass of 1992
Certifications & Licensure
GA State Medical License 2026 - 2028
MI State Medical License 1995 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Most Compassionate Doctor American Registry
Clinical Trials
- Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer Start of enrollment: 2001 Oct 01
- Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2001 Oct 01
- Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Start of enrollment: 2003 Aug 01
Publications & Presentations
PubMed
- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1.Joshua E Reuss, Nofisat Ismaila, Amith Ahluwalia, Toby Campbell, Jill Feldman
Journal of Clinical Oncology. 2026-06-20 - Longitudinal Treatment Outcomes in Patients With Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer: Results From a Multinational Registry-Based Study in...Khalil Choucair, Hayat Bazzi, Faten Abda, Farah Harb, Yasmin Snounu
JCO Global Oncology. 2026-06-01 - HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.David A Braun, Marcus S Noel, Ryan H Moy, Kurt Demel, Martin Gutierrez
Cell Reports. Medicine. 2026-05-19
Lectures
- S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).2019 ASCO Annual Meeting - 6/1/2019
- Management of Immunotherapy Toxicities in Patients With Lung Cancer2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Authored Content
- Second-Line Treatment Options in Non-Small Cell Lung Cancer (NSCLC): Report from an International Experts Panel Meeting of the Italian Association of Thoracic OncologyDecember 2017
Press Mentions
Life After Lung Cancer: Supporting Young Adults Through the Unique Challenges of SurvivorshipSeptember 29th, 2025- Navigating Early-Stage ALK+ Lung Cancer: Patient-Centered Strategies for Balancing Treatment and Quality of LifeSeptember 26th, 2025
- Managing Neurocognitive Side Effects in Patients with ALK+ NSCLC: What Oncology Nurses Should KnowSeptember 25th, 2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
